This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
msi-h
A collection of 51 issues
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer — Journal of Clinical Oncology
Long-term follow-up from the CheckMate 8HW phase 3 trial examined outcomes in patients with MSI-H/dMMR (microsatellite instability-high/mismatch repair-deficient) metastatic colorectal cancer treated with nivolumab plus ipilimumab versus
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
Skip to content
The CRC Digest
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy.
CRC Research Update — April 19, 2026
Today's colorectal cancer research highlights
AI-Based MSI Detection Shows Promise
Skip to content
The CRC Digest
AI-Based MSI Detection Shows Promise
Meta-analysis confirms deep learning tools can accurately identify MSI-H status, which determines eligibility for immunotherapy. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC
CRC Research Update — April 06, 2026
Today's colorectal cancer research highlights
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Skip to content
The CRC Digest
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Exceptional case of synchronous colon cancers with different MMR status provides direct in vivo evidence of ICI responsiveness differences. (Japanese Journal of Clinical Oncology)
This content is informational only and does